WO2005085218A1 - A novel process for preparing valdecoxib - Google Patents

A novel process for preparing valdecoxib Download PDF

Info

Publication number
WO2005085218A1
WO2005085218A1 PCT/IN2004/000053 IN2004000053W WO2005085218A1 WO 2005085218 A1 WO2005085218 A1 WO 2005085218A1 IN 2004000053 W IN2004000053 W IN 2004000053W WO 2005085218 A1 WO2005085218 A1 WO 2005085218A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
phenylisoxazolyl
ammonia
source
acid
Prior art date
Application number
PCT/IN2004/000053
Other languages
French (fr)
Inventor
Chandiran Thakashinamoorthy
Mercy Gnanadeepam Jesudoss
Meera Hariharasubramanian
Subramanian Sankara Seetharaman
Original Assignee
Chandiran Thakashinamoorthy
Mercy Gnanadeepam Jesudoss
Meera Hariharasubramanian
Seetharaman Subramanian Sankar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chandiran Thakashinamoorthy, Mercy Gnanadeepam Jesudoss, Meera Hariharasubramanian, Seetharaman Subramanian Sankar filed Critical Chandiran Thakashinamoorthy
Priority to PCT/IN2004/000053 priority Critical patent/WO2005085218A1/en
Publication of WO2005085218A1 publication Critical patent/WO2005085218A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Definitions

  • the present invention relates to a novel process for making 4-[5-methyl-3- phenylisoxazol-4-yl] benzenesulphonamide (hereinafter referred as valdecoxib).
  • Compounds of formula I are useful for but not limited to the treatment of inflammation in a subject and for the treatment of other inflammation associated disorders such as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever.
  • Methods for preparing substituted iso-oxazol -4-yl benzenesulfonamide compounds are also described in US Patent No. 5,859,257. This patent describes processes for making valdecoxib by treatment of the 3,4 di-phenyl - 4-hydrido-5-hydroxy-5-methylisoxazole with large excess chlorosulfonic acid to make aromatic sulphonyl chloride and adding liquid ammonia to this sulphonyl chloride to get the desired compound
  • This invention discloses a process for preparing valdecoxib by reacting 3,4-diphenyl-5- methylisoxazole or 5-hydroxy-5-methyl-3,4-diphenylisoxazoline with halosulfonic acid in the presence of trifluoroacetic acid to produce a halosulfonated product and then contacting the halosulfonated product with a source of ammonia to produce valdecoxib.
  • This process overcomes the reactivity issues by using trifluoroacetic acid as a medium for dissolution before adding chlorosulfonic acid.
  • the object of the present invention is therefore to provide for a process for preparing valdecoxib, which reaction can be carried out at a lower temperature thus avoiding formation of isomeric impurities, while also overcoming reactivity issues.
  • valdecoxib 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonamide
  • Figure 1 shows a process by which 4-[5-methyl-3-phenylisoxazol-4- yl]benzenesulphonamide of formulal can be prepared according to the present invention.
  • Step la sulfonation of either 3,4-diphenyl-5-methylisoxazole or 5-hydroxy-5- methyl-3,4-diphenylisoxazoline using oleum to get corresponding sulfonic acid; which is then converted in to 4-[(5-methyl-3-pheny ⁇ )-4- isoxazolyl]benzenesulfonate sodium salt using sodium chloride.
  • step lb The sodium salt is then converted into the corresponding sulphonyl halide using a halogenating agent (Step2), which is then treated with ammonia to get valdecoxib (step 3).
  • the starting materials for use in the methods of preparation of the invention are known and can be prepared by conventional methods known to a skilled person or in an analogous manner to processes described in the art.
  • the requisite starting isoxazole or isoxazoline can also be obtained commercially by synthesis using methods disclosed as in EP 0026928 and in US Patent No. 5,859,257.
  • step la The sulfonation of isoxazole or isoxazoline (step la) is carried out using 10 - 40 % oleum as sulfonating agent in sulfuric acid medium to get 4-[(5-methyl-3- phenyl)-4-isoxazolyl]benzenesulfonic acid.
  • Sulfuric acid is used to dilute the oleum as well as act as the reaction medium for the sulfonation reaction.
  • For sulfonation around 1 to 6 mol of S0 3 is used, and preferably 2 to 3 mol of S0 3 is used, and the reaction can be carried out above the freezing point of the reaction mass.
  • the sulfonation of the present invention is carried out at 0 to 40°C, preferably at 5 to 15°C.
  • the product is obtained from the reaction mixture by diluting the reaction mass with water till concentration of the sulfuric acid after dilution is around 30 to 70%. And more preferably, the sulfuric acid concentration is adjusted to 40 to 60% precipitate the product from the reaction mixture.
  • the precipitation of the 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonic acid is carried out at 0 to 40°C and more preferably at 10 to 20° C, and the product is separated by filtration or centrifugation of the slurry.
  • oleum as the sulfonating agent is that it allows for reaction to be carried out at a lower temperature thus avoiding formation of isomeric impurities. Further the reactivity issues are also overcome, as the starting material is freely soluble in oleum.
  • the obtained sulfonic acid is then converted in its corresponding sodium salt by dissolving it in water at 0 to 40 °C, and then treating with sodium chloride (step lb).
  • the dissolution may be carried in 2 to 10 ml water per 1 g of the sulfonic acid and preferably in 4 to 5 ml of water at 25 to 30°C.
  • the sulfonic acid solution is then saturated with sodium chloride and cooled to 0 to 10°C to crystallize the 4-[(5-methyl-3-phenyl) -isoxazolyl]benzenesulfonate sodium salt from the reaction mixture.
  • the product is filtered, dried under vacuum and analyzed. (HPLC purity analysis: greater than 99%).
  • sulfonic acid sodium salt has several advantages since the sulphonic acid is very hygroscopic in nature, and thus cannot be taken directly for the halogenation step. Further isolating it is a sodium salt enables purification of the sulphonic acid, and this being non-hygroscopic allows for ease in drying and handling of the material.
  • the sulfonate sodium salt is then converted in to sulfonyl halide using halogenating agents such as SOCl 2 , SOBr 2 , PC1 5 , POCl 3 , etc.
  • halogenating agents such as SOCl 2 , SOBr 2 , PC1 5 , POCl 3 , etc.
  • 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonate sodium is converted to 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonyl chloride using SOCl 2 in the presence of catalytic amount of dimethylformamide (step 2).
  • the halogenating agent is used in 1.0 to 4.0 mol per mole of the sulfonate salt.
  • the halogenation reaction may be carried out in chlorinated solvents such as dichloromethane, chlorobenzene and hydrocarbon solvents such as toluene or in the excess of halogenating agent itself as solvent.
  • the halogenation reaction may be carried out at 30 to 120°C and preferably at 60 to 90°C.
  • the reaction mixture may be washed with water after completion of the halogenation to remove the excess halogenating agent and sodium chloride to get the sulfonyl halide in the solution.
  • the 4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonyl halide solution may be as such taken for the reaction with ammonia or if preferred the 4-[(5- methyl-3-phenyl)-4-isoxazofyl]benzenesulfonyl halide can be isolated from the solution by evaporation of the solvent and then it is purified before further reaction with ammonia. Isolation of the sulphonyl chloride allows for color removal and also purification prior to the last step, so as to obtain pharmaceutically acceptable final product directly without need for further re- crystallization steps to remove impurities.
  • sulfonyl halide obtained from the above step is reacted with ammonia in a suitable solvent to get valdecoxib.
  • a suitable solvent in a preferred embodiment dichloromethane or toluene is used as solvent for the reaction to obtain valdecoxib.
  • the reaction may be carried out by adding aqueous ammonia or anhydrous ammonia in to the solution of 4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonyl halide, or by passing ammonia gas in to the solution of 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonyl halide.
  • the solution of 4- ⁇ (5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonyl halide is added in to aqueous ammonia.
  • the reaction may be carried out at -10 to 40° C and preferably at 0 to 10°C.
  • the reaction mixture is washed with water and then the solvent is partially removed by distillation to get the product crystallized.
  • the product is then filtered and dried to obtain valdecoxib.
  • process methods of the present invention can be performed as follows. Larger scale preparation can be performed, for example, by proportionately increasing ingredient quantities.
  • reaction mass is then slowly added in to ice water (187 ml) drop by drop by maintaining the temperature 10 to 20° C.
  • the content is then stirred for 5-7 hr at 0 - 5°C to complete the precipitation of the product.
  • the product obtained is then filtered and suck dried to obtain a 4-(5-methyl-3- phenyl-4-isoxazolyl)benzene sulfonic acid as wet product (48g, HPLC purity 99.2%)
  • the sulphonic acid obtained in example 1 is dissolved in 185 ml water and sodium chloride (37 g, 0.6324 mol) is added portion wise at a temperature of 25-30 °C.
  • the turbid reaction mass is then cooled to 0-5 °C, stirred for 2 h and filtered.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relatesto a novel process for making 4-[5-methyl -3-phenylisoxazol-4-yl] benzenesulphonamide

Description

A NOVEL PROCESS FOR PREPARING VALDECOXIB
FIELD OF THE INVENTION
The present invention relates to a novel process for making 4-[5-methyl-3- phenylisoxazol-4-yl] benzenesulphonamide (hereinafter referred as valdecoxib).
BACKGROUND OF THE INVENTION
US Patent 5,633,272 which is incorporated herein by reference, discloses substituted isoxoazolyl compounds, particularly 4-[5-methyl-3-phenylisoxazol- 4-yl] benzenesulphonamide of the Formula 1,
Figure imgf000002_0001
useful in the treatment of inflammation.
Compounds of formula I are useful for but not limited to the treatment of inflammation in a subject and for the treatment of other inflammation associated disorders such as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever. Methods for preparing substituted iso-oxazol -4-yl benzenesulfonamide compounds are also described in US Patent No. 5,859,257. This patent describes processes for making valdecoxib by treatment of the 3,4 di-phenyl - 4-hydrido-5-hydroxy-5-methylisoxazole with large excess chlorosulfonic acid to make aromatic sulphonyl chloride and adding liquid ammonia to this sulphonyl chloride to get the desired compound
However, insolubility of the isoxazoline compound in chlorosulphonic acid poses reactivity issues. International publication WO 03/029230, describes a process for preparing aromatic sulfonyl halides by contacting a substituted phenyl compound with a halosulfonic with trifluororacetic acid. This invention discloses a process for preparing valdecoxib by reacting 3,4-diphenyl-5- methylisoxazole or 5-hydroxy-5-methyl-3,4-diphenylisoxazoline with halosulfonic acid in the presence of trifluoroacetic acid to produce a halosulfonated product and then contacting the halosulfonated product with a source of ammonia to produce valdecoxib. This process overcomes the reactivity issues by using trifluoroacetic acid as a medium for dissolution before adding chlorosulfonic acid. Although adding trifluoroacetic acid also aids halosulfonation reaction to be carried out at higher temperatures and thereby shortens reaction time, it is to be noted that performing this halosulfonation reaction at higher temperatures causes formation of isomeric impurity (meta sulphonyl chloride). Clearly there is a need for alternate processes for making valdecoxib that overcome these problems of reactivity and impurities. The object of the present invention is therefore to provide for a process for preparing valdecoxib, which reaction can be carried out at a lower temperature thus avoiding formation of isomeric impurities, while also overcoming reactivity issues.
SUMMARY OF THE INVENTION
The aforesaid objective is achieved by the present invention which provides a novel method for the preparation of 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonamide (hereinafter referred as valdecoxib) consisting of:
- sulfonation of either 3,4-diphenyl-5-methylisoxazole or 5-hydroxy-5- methyl-3,4-diphenylisoxazoline using oleum to get the sulfonic acid derivative; - purification of the sulphonic acid derivative as its sodium salt; halogenating the sodium salt to the corresponding sulfonylhalide; and - treating the aromatic sulphonyl halide with ammonia to get the desired compound.
Further the scope and applicability of the present invention will become apparent from the detailed description provided below. However, it should be understood that the following detailed description and examples, while indicating preferred embodiments of the invention, are given by way of illustration only since various changes and modification within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. Brief description of the figure
Figure 1 shows a process by which 4-[5-methyl-3-phenylisoxazol-4- yl]benzenesulphonamide of formulal can be prepared according to the present invention.
Detailed description of the preferred embodiments
The following detailed description is provided to aid those skilled in the art in practicing the present invention. Even so, this detailed description should not be construed to unduly limit the present invention as modifications and variations in the embodiments discussed herein can be made by those of ordinary skill in the art without departing from the spirit and scope of the present invention.
The contents of each reference cited herein including the contents of the references cited within these primary references are herein incorporated by reference in their entirety.
The synthesis of valdecoxib can be summarized by the following reaction scheme as shown in figure 1: Step la: sulfonation of either 3,4-diphenyl-5-methylisoxazole or 5-hydroxy-5- methyl-3,4-diphenylisoxazoline using oleum to get corresponding sulfonic acid; which is then converted in to 4-[(5-methyl-3-phenyι)-4- isoxazolyl]benzenesulfonate sodium salt using sodium chloride. (step lb) The sodium salt is then converted into the corresponding sulphonyl halide using a halogenating agent (Step2), which is then treated with ammonia to get valdecoxib (step 3).
The starting materials for use in the methods of preparation of the invention are known and can be prepared by conventional methods known to a skilled person or in an analogous manner to processes described in the art. The requisite starting isoxazole or isoxazoline can also be obtained commercially by synthesis using methods disclosed as in EP 0026928 and in US Patent No. 5,859,257.
The sulfonation of isoxazole or isoxazoline (step la) is carried out using 10 - 40 % oleum as sulfonating agent in sulfuric acid medium to get 4-[(5-methyl-3- phenyl)-4-isoxazolyl]benzenesulfonic acid. Sulfuric acid is used to dilute the oleum as well as act as the reaction medium for the sulfonation reaction. For sulfonation around 1 to 6 mol of S03 is used, and preferably 2 to 3 mol of S03 is used, and the reaction can be carried out above the freezing point of the reaction mass. In general the sulfonation of the present invention is carried out at 0 to 40°C, preferably at 5 to 15°C. The product is obtained from the reaction mixture by diluting the reaction mass with water till concentration of the sulfuric acid after dilution is around 30 to 70%. And more preferably, the sulfuric acid concentration is adjusted to 40 to 60% precipitate the product from the reaction mixture. The precipitation of the 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonic acid is carried out at 0 to 40°C and more preferably at 10 to 20° C, and the product is separated by filtration or centrifugation of the slurry. Advantage of using oleum as the sulfonating agent is that it allows for reaction to be carried out at a lower temperature thus avoiding formation of isomeric impurities. Further the reactivity issues are also overcome, as the starting material is freely soluble in oleum.
The obtained sulfonic acid is then converted in its corresponding sodium salt by dissolving it in water at 0 to 40 °C, and then treating with sodium chloride (step lb). The dissolution may be carried in 2 to 10 ml water per 1 g of the sulfonic acid and preferably in 4 to 5 ml of water at 25 to 30°C. The sulfonic acid solution is then saturated with sodium chloride and cooled to 0 to 10°C to crystallize the 4-[(5-methyl-3-phenyl) -isoxazolyl]benzenesulfonate sodium salt from the reaction mixture. The product is filtered, dried under vacuum and analyzed. (HPLC purity analysis: greater than 99%). Making the sulfonic acid sodium salt has several advantages since the sulphonic acid is very hygroscopic in nature, and thus cannot be taken directly for the halogenation step. Further isolating it is a sodium salt enables purification of the sulphonic acid, and this being non-hygroscopic allows for ease in drying and handling of the material.
The sulfonate sodium salt is then converted in to sulfonyl halide using halogenating agents such as SOCl2, SOBr2, PC15, POCl3, etc. In a preferred embodiment of the present invention 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonate sodium is converted to 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonyl chloride using SOCl2 in the presence of catalytic amount of dimethylformamide (step 2). The halogenating agent is used in 1.0 to 4.0 mol per mole of the sulfonate salt. The halogenation reaction may be carried out in chlorinated solvents such as dichloromethane, chlorobenzene and hydrocarbon solvents such as toluene or in the excess of halogenating agent itself as solvent. The halogenation reaction may be carried out at 30 to 120°C and preferably at 60 to 90°C. The reaction mixture may be washed with water after completion of the halogenation to remove the excess halogenating agent and sodium chloride to get the sulfonyl halide in the solution.
The 4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonyl halide solution may be as such taken for the reaction with ammonia or if preferred the 4-[(5- methyl-3-phenyl)-4-isoxazofyl]benzenesulfonyl halide can be isolated from the solution by evaporation of the solvent and then it is purified before further reaction with ammonia. Isolation of the sulphonyl chloride allows for color removal and also purification prior to the last step, so as to obtain pharmaceutically acceptable final product directly without need for further re- crystallization steps to remove impurities.
Pure sulfonyl halide obtained from the above step is reacted with ammonia in a suitable solvent to get valdecoxib. In a preferred embodiment dichloromethane or toluene is used as solvent for the reaction to obtain valdecoxib. The reaction may be carried out by adding aqueous ammonia or anhydrous ammonia in to the solution of 4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonyl halide, or by passing ammonia gas in to the solution of 4-[(5-methyl-3-phenyl)-4- isoxazolyl]benzenesulfonyl halide. In another embodiment of the present invention the solution of 4-{(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonyl halide is added in to aqueous ammonia. The reaction may be carried out at -10 to 40° C and preferably at 0 to 10°C. The reaction mixture is washed with water and then the solvent is partially removed by distillation to get the product crystallized. The product is then filtered and dried to obtain valdecoxib. The following examples are intended to be illustrative of the many embodiments of the present invention and are not meant to be limiting in scope.
Generally, the process methods of the present invention can be performed as follows. Larger scale preparation can be performed, for example, by proportionately increasing ingredient quantities.
EXAMPLE 1:
4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzene sulfonic acid, (step la)
Charged concentrated sulfuric acid (98% w/w, 74ml) in a dry 250 ml four neck RB flask. Added in to it 5-methyl-3,4,diphenylisoxazole (37g, 0.1575 mol) at 25°C. After the addition, the mass is stirred for 15 to 20 min. at 25°C to obtain a clear solution. The reaction mass is cooled to 5° C and oleum (20% w/w, 81.4ml) is added drop-wise by maintaining the temperature 5 - 10°C. After the addition the mass is stirred at 5 - 10°C for an hour. HPLC showed completion of reaction. The reaction mass is then slowly added in to ice water (187 ml) drop by drop by maintaining the temperature 10 to 20° C. The content is then stirred for 5-7 hr at 0 - 5°C to complete the precipitation of the product. The product obtained is then filtered and suck dried to obtain a 4-(5-methyl-3- phenyl-4-isoxazolyl)benzene sulfonic acid as wet product (48g, HPLC purity 99.2%)
EXAMPLE 2: 4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonate sodium salt, (step lb)
The sulphonic acid obtained in example 1 is dissolved in 185 ml water and sodium chloride (37 g, 0.6324 mol) is added portion wise at a temperature of 25-30 °C. The turbid reaction mass is then cooled to 0-5 °C, stirred for 2 h and filtered. The wet material is then washed with chilled water (74 ml) and dried at 70-75 °C under vacuum for 8-10 h to yield white solid. (38 g, HPLC purity = 99.5%, Moisture content = 4.6% )
EXAMPLE 3:
Preparation of 4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonyl chloride (step 2)
4-(5-methyl-3-phenyl-4-isoxazolyl)benzene sulfuric acid sodium salt (15 g, 0.0445 mol), toluene (300 ml), thionyl chloride (11.3 ml, 0.1548 mol) & catalytic quantity of DMF(0.8 ml) are taken together and heated to 70-75 °C temperature for 2hours. HPLC analysis of the reaction mass showed starting material less than 2%. The reaction mass is then cooled to 5- 10 °C and water (100 ml) is added and stirred for 15 min. The aqueous and organic layers are separated, the organic layer washed with water (100 ml). The organic layer is dried over sodium sulphate and filtered. The organic layer is distilled under vacuum to remove toluene completely to get crude product (14g). To the crude product (14g) is dissolved in diisopropyl ether (250 ml) at reflux and treated with activated carbon (0.8g) for 15 min. The content is then filtered through flash silica gel (230-400 mesh). The mother liquor is cooled to 0-5°C and stirred for an hour to get the crystallization completed. The product is filtered, washed with diisopropyl ether (50 ml). The product obtained is then dried under vacuum at 50-55°C (8.3g, HPLC purity = 97.7%)
EXAMPLE 4
4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (step 3)
Charged 400 ml of dichloromethane in a dry 1L four neck round bottom flask, into this 7.8 g of sulfonyl chloride from example 3 (0.02296 mol) was added at room temperature and stirred well. Reaαion mass cooled to 0°C and ammonia gas was purged for an hour, during this white solid was formed in the reaction mass. After one hour analysed by HPLC showed completion of reaction. Reaction mass allowed to come to room temperature and dichloromethane layer is washed thrice with water (3 x 100 ml). Dried over anhydrous sodium sulfate and filtered. Dichloromethane is distilled to obtain a one fourth of the initial volume and then cooled to 0 to 5°C to get the product crystallised. The product is then filtered and washed with pre-cooled dichloromethane (2 x 10 ml) and the product dried under vacuum at 60 to 70 °C to obtain a crystalline product (5.6 g, HPLC purity = 99.7%).

Claims

We claim;
1. A method of preparing 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulphonamide of formula 1 comprising: contacting a precursor compound selected from the group consisting of Formula 2 and Formula 3 with a sulfonating agent to form 4-[5-methyl-3- phenylisoxazolyl] benzenesulfonic acid,
Figure imgf000012_0001
2 3 - optionally, treating 4-[5-methyl-3-phenylisoxazolyl] benzenesulphonic acid with a source of alkali metal to obtain 4-[5-methyl-3-phenylisoxazolyl] benzenesulfonate sodium salt; converting 4-[5-methyl-3-phenylisoxazolyl] benzenesulfonate sodium salt or 4-[5-methyl-3-phenylisoxazolyl] benzenesulfonic acid to 4-[5-methyl-3- phenylisoxazolyl] benzenesulfonyl chloride by contacting the sulfonate salt or sulfonic acid, with a halogenating agent, and contacting the 4-[5-methyl-3-phenylisoxazolyl] benzenesulfonyl chloride with a source of ammonia to produce 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulphonamide.
2. The method according to claim 1 wherein the sulfonating agent is oleum.
3. A method according to claim 1 wherein the source of alkali metal is sodium chloride.
4. A method according to claim 1 wherein the halogenating agent is selected from SOCl2,SOBr2,PCl5,POCl3.
5. A method according to claim 1 wherein the halogenating agent is thionyl chloride.
6. A method according to claim 1 wherein the source of ammonia is selected from ammonium hydroxide or anhydrous ammonia.
7. A method according to claim 6 wherein the source of ammonia is ammonium hydroxide .
8. A method according to claim 6 wherein the source of ammonia is anhydrous ammonia.
9. A method according to claim 1 wherein sulfonation is carried out using 10 - 40 % oleum as sulfonating agent in sulfuric acid medium
10. A method as claimed in claim 1 wherein the amount of halogentaing agent used is between about 1.0 to 4.0 mol per mole of the sulfonate salt.
11. A method as claimed in any one of claims 1,4,5 or 10 wherein the halogenation reaction is carried out in chlorinated solvents
2. A method as claimed in claim 11 wherein chlorinated solvent include dichloromethane, chlorobenzene and toluene
PCT/IN2004/000053 2004-03-05 2004-03-05 A novel process for preparing valdecoxib WO2005085218A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000053 WO2005085218A1 (en) 2004-03-05 2004-03-05 A novel process for preparing valdecoxib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000053 WO2005085218A1 (en) 2004-03-05 2004-03-05 A novel process for preparing valdecoxib

Publications (1)

Publication Number Publication Date
WO2005085218A1 true WO2005085218A1 (en) 2005-09-15

Family

ID=34917514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000053 WO2005085218A1 (en) 2004-03-05 2004-03-05 A novel process for preparing valdecoxib

Country Status (1)

Country Link
WO (1) WO2005085218A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130919A (en) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 Method and equipment for preparing 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonyl chloride
CN105651927A (en) * 2014-11-14 2016-06-08 泰州复旦张江药业有限公司 An RT-HPLC detecting method for valdecoxib/parecoxib related substances
CN108299331A (en) * 2018-03-02 2018-07-20 成都新恒创药业有限公司 A kind of Parecoxib Sodium light degradation impurity and its preparation, detection method and application
CN105418528B (en) * 2015-12-31 2018-08-24 山东罗欣药业集团股份有限公司 A kind of preparation method of Parecoxib Sodium
CN110305069A (en) * 2019-07-02 2019-10-08 中国乐凯集团有限公司 A kind of preparation method of 3-(5-mercapto-1-tetrazolyl) benzenesulfonyl chloride
CN113773270A (en) * 2021-08-06 2021-12-10 四川新开元制药有限公司 Synthesis method of parecoxib sodium impurity
CN114441666A (en) * 2020-11-05 2022-05-06 成都百裕制药股份有限公司 Method for detecting impurities in 4- (5-methyl-3-phenyl-4-isoxazole) benzenesulfonyl chloride
CN114634457A (en) * 2022-04-21 2022-06-17 济南立德医药技术有限公司 Refining method of valdecoxib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105334A1 (en) * 2001-10-02 2003-06-05 Letendre Leo J. Method for preparing benzenesulfonyl compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105334A1 (en) * 2001-10-02 2003-06-05 Letendre Leo J. Method for preparing benzenesulfonyl compounds

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105651927A (en) * 2014-11-14 2016-06-08 泰州复旦张江药业有限公司 An RT-HPLC detecting method for valdecoxib/parecoxib related substances
CN105130919A (en) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 Method and equipment for preparing 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonyl chloride
CN105130919B (en) * 2015-09-11 2017-04-19 江苏嘉逸医药有限公司 Method and equipment for preparing 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonyl chloride
CN105418528B (en) * 2015-12-31 2018-08-24 山东罗欣药业集团股份有限公司 A kind of preparation method of Parecoxib Sodium
CN108299331A (en) * 2018-03-02 2018-07-20 成都新恒创药业有限公司 A kind of Parecoxib Sodium light degradation impurity and its preparation, detection method and application
CN110305069A (en) * 2019-07-02 2019-10-08 中国乐凯集团有限公司 A kind of preparation method of 3-(5-mercapto-1-tetrazolyl) benzenesulfonyl chloride
CN110305069B (en) * 2019-07-02 2022-09-16 中国乐凯集团有限公司 Preparation method of 3- (5-mercapto-1-tetrazolyl) benzenesulfonyl chloride
CN114441666A (en) * 2020-11-05 2022-05-06 成都百裕制药股份有限公司 Method for detecting impurities in 4- (5-methyl-3-phenyl-4-isoxazole) benzenesulfonyl chloride
CN114441666B (en) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 Method for detecting impurities in 4- (5-methyl-3-phenyl-4-isoxazole) benzenesulfonyl chloride
CN113773270A (en) * 2021-08-06 2021-12-10 四川新开元制药有限公司 Synthesis method of parecoxib sodium impurity
CN113773270B (en) * 2021-08-06 2024-05-31 四川新开元制药有限公司 A kind of synthetic method of 3-(5-methyl-4-phenylisoxazol-3-yl)benzenesulfonamide
CN114634457A (en) * 2022-04-21 2022-06-17 济南立德医药技术有限公司 Refining method of valdecoxib

Similar Documents

Publication Publication Date Title
CN108314634A (en) The method that taurine is prepared by alkali metal isethionate salt and vinyl sulfonic acid alkali metal salt cycle
WO2005085218A1 (en) A novel process for preparing valdecoxib
BRPI0111255B1 (en) Process for the preparation of a sulfonamide
CN117263925A (en) Synthesis method of pyrifos
KR20030082946A (en) Process for the preparation of 1,2-benzisoxazole-3-acetic acid
JP2839653B2 (en) Method for producing aromatic sulfonyl chloride
EP1550658A1 (en) Method for preparing 3,4-diphenyl-substituted isoxazole compounds
US7109353B2 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
DK171809B1 (en) Process for the preparation of alkanesulfonamides
KR100362590B1 (en) Method for producing 1,2-Naphthoquinone-2-diazide-4-sulfonyl chloride
JPH0244303B2 (en)
CN111153866A (en) Parecoxib sodium disubstituted impurity and preparation method and application thereof
CN103923070A (en) Efficient Process For The Preparation Of Lapatinib And Salts Thereof By Means Of New Intermediates
KR101170192B1 (en) One-pot process for producing 1,2-benzisoxazole-3-methanesulfonamide
JP3089373B2 (en) Method for producing 2-mercapto-phenothiazine
JPH02169561A (en) Production of 3-trifluoromethylbenzene sulfonyl chlorides
SK286031B6 (en) Method for the preparation of 2-methoxy-4-(N-t- butylaminocarbonyl)benzenesulfonyl chloride
KR100402055B1 (en) A process for preparing Glibenclamide
MX2007007923A (en) PROCESS FOR PREPARING 5,6-DIHYDRO-4-(S)-(ETHYLAMINO)-6-(S) METHYL-4H-THIENO[2,3b]THIOPYRAN-2-SULPHONAMIDE-7,7-DIOXIDE HCI.
JPH026460A (en) Production of c1 - c6 alkane sulfonic acid
JP2003517029A (en) Method for producing trifluoromethylacetophenone
JPH06345717A (en) Method for purifying aminoethanesulfonic acids
JPH02204476A (en) Production of benzenesulfonyl chloride derivative
JPH10316646A (en) Production of high-purity crystalline o-methyliso urea acetate and crystalline o-methylisourea acetate obtained by the same
JPS6222980B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase